-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Maintains Overweight on PTC Therapeutics, Raises Price Target to $112

Benzinga·10/30/2026 16:56:00
Listen to the news
Wells Fargo analyst Benjamin Burnett maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from $109 to $112.